Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Melissa Grozinski‐Wolff
Observed names:
M. Grozinski-Wolff,
Melissa Grozinski-Wolff
Observed institutions:
Thomas Jefferson University,
King's College London,
Mayo Clinic in Arizona,
Teva Pharmaceuticals (United States),
Wellcome Trust
OpenAlex ID:
A5044997689
Fremanezumab for the Preventive Treatment of Chronic Migraine
2017
·
Stephen D. Silberstein
, David W. Dodick
, et al.
·
New England Journal of Medicine
·
794
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
2018
·
David W. Dodick
, Stephen D. Silberstein
, et al.
·
JAMA
·
564
PDF
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
2019
·
Michel D Ferrari
, Hans Christoph Diener
, et al.
·
The Lancet
·
417
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine
2019
·
Paul K. Winner
, Egilius L. H. Spierings
, et al.
·
Headache The Journal of Head and Face Pain
·
47
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
2019
·
Jan Lewis Brandes
, David Kudrow
, et al.
·
Cephalalgia
·
23
Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.107)
2018
·
Jan Brandes
, Paul P. Yeung
, et al.
·
Neurology
·
3
Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (P4.102)
2018
·
Paul P. Yeung
, Ernesto Aycardi
, et al.
·
Neurology
·
2
Safety Outcomes from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents
2025
·
A. D. Hershey
, C. L. Szperka
, et al.
·
Neuropediatrics
Efficacy Outcomes from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents
2025
·
A. D. Hershey
, C. L. Szperka
, et al.
·
Neuropediatrics
Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)
2018
·
Stephen Silberstein
, Ernesto Aycardi
, et al.
·
Neurology
Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)
2018
·
David Dodick
, Ernesto Aycardi
, et al.
·
Neurology
Impact of Fremanezumab on the Number of Days With Use of Acute Headache Medications in Episodic Migraine (P4.106)
2018
·
Jan Brandes
, Fumihiko Sakai
, et al.
·
Neurology
Achievement of Response with Fremanezumab in the Treatment of Chronic Migraine (P4.113)
2018
·
Paul K. Winner
, Marcelo E. Bigal
, et al.
·
Neurology
Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine (P4.101)
2018
·
Ernesto Aycardi
, Paul P. Yeung
, et al.
·
Neurology
Show more works
View as search
Works count:
14
Citation count:
1,850
H-index:
5
I10-index:
5
Year
Topic
Type
